Henry Ford Health

Henry Ford Health Scholarly Commons
Cardiology Articles

Cardiology/Cardiovascular Research

5-1-2021

Clinical outcomes and healthcare expenditures in the real world
with left ventricular assist devices - The CLEAR-LVAD study
Francis D. Pagani
Mandeep R. Mehra
Jennifer A. Cowger
Henry Ford Health, jcowger1@hfhs.org

Douglas A. Horstmanshof
Scott C. Silvestry

See next page for additional authors

Follow this and additional works at: https://scholarlycommons.henryford.com/cardiology_articles

Recommended Citation
Pagani FD, Mehra MR, Cowger JA, Horstmanshof DA, Silvestry SC, Atluri P, Cleveland JC, Jr., Lindenfeld J,
Roberts GJ, Bharmi R, Dalal N, Kormos RL, and Rogers JG. Clinical outcomes and healthcare expenditures
in the real world with left ventricular assist devices - The CLEAR-LVAD study. J Heart Lung Transplant
2021; 40(5):323-333.

This Article is brought to you for free and open access by the Cardiology/Cardiovascular Research at Henry Ford
Health Scholarly Commons. It has been accepted for inclusion in Cardiology Articles by an authorized
administrator of Henry Ford Health Scholarly Commons.

Authors
Francis D. Pagani, Mandeep R. Mehra, Jennifer A. Cowger, Douglas A. Horstmanshof, Scott C. Silvestry,
Pavan Atluri, Joseph C. Cleveland, JoAnn Lindenfeld, Gregory J. Roberts, Rupinder Bharmi, Nirav Dalal,
Robert L. Kormos, and Joseph G. Rogers

This article is available at Henry Ford Health Scholarly Commons: https://scholarlycommons.henryford.com/
cardiology_articles/760

TagedEn

TagedFiur

TagedEn

TagedFiur
http://www.jhltonline.org

ORIGINAL CLINICAL SCIENCE

TagedH1Clinical outcomes and healthcare expenditures
in the real world with left ventricular assist
devices − The CLEAR-LVAD studyTagedEn
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BACKGROUND: Several distinctly engineered left ventricular assist devices (LVADs) are in clinical use.
However, contemporaneous real world comparisons have not been conducted, and clinical trials were
not powered to evaluate differential survival outcomes across devices.
OBJECTIVES: Determine real world survival outcomes and healthcare expenditures for commercially
available durable LVADs.
METHODS: Using a retrospective observational cohort design, Medicare claims files were linked to manufacturer device registration data to identify de-novo, durable LVAD implants performed between January
2014 and December 2018, with follow-up through December 2019. Survival outcomes were compared
using a Cox proportional hazards model stratified by LVAD type and validated using propensity score
matching. Healthcare resource utilization was analyzed across device types by using nonparametric bootstrap analysis methodology. Primary outcome was survival at 1-year and total Part A Medicare payments.
RESULTS: A total of 4,195 de-novo LVAD implants were identified in fee-for-service Medicare beneficiaries (821 HeartMate 3; 1,840 HeartMate II; and 1,534 Other-VADs). The adjusted hazard ratio for
mortality at 1-year (confirmed in a propensity score matched analysis) for the HeartMate 3 vs HeartMate II was 0.64 (95% CI; 0.52−0.79, p< 0.001) and for the HeartMate 3 vs Other-VADs was 0.51
(95% CI; 0.42−0.63, p < 0.001). The HeartMate 3 cohort experienced fewer hospitalizations per
patient-year vs Other-VADs (respectively, 2.8 vs 3.2 EPPY hospitalizations, p < 0.01) and 6.1 fewer
hospital days on average (respectively, 25.2 vs 31.3 days, p < 0.01). The difference in Medicare expenditures, conditional on survival, for HeartMate 3 vs HeartMate II was -$10,722, p < 0.001 (17.4%
reduction) and for HeartMate 3 vs Other-VADs was -$17,947, p < 0.001 (26.1% reduction).
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CONCLUSIONS: In this analysis of a large, real world, United States. administrative dataset of durable
LVADs, we observed that the HeartMate 3 had superior survival, reduced healthcare resource use, and
lower healthcare expenditure compared to other contemporary commercially available LVADs.
J Heart Lung Transplant 2021;40:323−333
Ó 2021 The Author(s). Published by Elsevier Inc. on behalf of International Society for Heart and Lung
Transplantation. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/)
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TagedPCondensed abstractTagedEn
TagedPA real world comparative effectiveness study was conducted among commercially available durable left ventricular
assist devices (LVADs). Medicare claims files were linked to
manufacturer device registration data to identify de-novo,
implants to assess 1-year survival and healthcare expenditures. Among 4,195 de-novo implants (821 HeartMate 3,
(HM3); 1,840 HeartMate II, (HMII); and 1,534 OtherVADs), the adjusted mortality at 1-year for the HM3 was
superior to HMII and Other-VADs. The HM3 cohort experienced fewer hospitalizations and less Medicare expenditures
vs Other-VADs. In a large, real world, United States (U.S.)
administrative dataset, we observed the HM3 to have superior
survival and lower healthcare expenditures.TagedEn

TagedH1IntroductionTagedEn
TagedPThe evidentiary basis for device selection in patients with
advanced heart failure receiving durable left ventricular
assist device (LVAD) support has largely accrued from randomized controlled clinical trials.1-4 The largest such trial,
the Multicenter Study of MagLev Technology in Patients
Undergoing MCS Therapy With HeartMate 3 Investigational Device Exemption Clinical Study (MOMENTUM 3)
evaluated 1028 patients and demonstrated that a fully magnetically levitated centrifugal continuous flow pump (HeartMate 3; HM3; Abbott Labs, Chicago, IL) was superior to a
mechanical bearing axial continuous flow pump (HeartMate
II; HMII; Abbott Labs, Chicago, IL) with regard to 2-year
survival free of disabling stroke or need for device reoperation or replacement for a malfunctioning device.3 Similarly,
The HeartWare Ventricular Assist System as Destination
Therapy of Advanced Heart Failure: the ENDURANCE
Trial (ENDURANCE) compared a smaller intrapericardial
device (i.e., HVAD System; Medtronic, Inc., Minneapolis,
MN) to the HMII in 446 patients and demonstrated noninferiority of the primary end point of survival at 2 years free

from disabling stroke or device removal for malfunction or
failure.4 These trials were not powered to evaluate the various LVADs on the end-point of mortality alone.TagedEn
TagedPWith the real world use and dissemination of LVAD
therapy beyond clinical trial-defined populations, device
performance and outcomes have differed from those
observed within clinical trials.5-7 Conversely, increasing
surgical experience has demonstrated improved outcomes
beyond those of the early clinical trials.8 Real world data
can provide important opportunities for comparative effectiveness analyses when data is lacking or to supplement
findings from randomized clinical trials.9,10TagedEn
TagedPMedicare is the federal health insurance program in the
U.S. for those aged ≥65 years, <65 years of age with disabilities, or with end-stage renal disease. Administrative
claims files from Medicare have been used to perform comparative effectiveness studies of various therapies and to
describe their associated patterns of morbidity and mortality, and healthcare expenditures associated with care.11TagedEn
TagedPIn the ClinicaL OutcomEs and HealthcAre Expenditures
in the Real World with Left Ventricular Assist Devices
(CLEAR-LVAD) study, we used a combination of Medicare claims files and manufacturer device registration data
to: (1) investigate the real world effectiveness of commercially available durable LVADs on survival and postimplant hospitalizations; and (2) investigate differences in
healthcare resource utilization and attendant expenditure
among commercially available LVADs. We hypothesized
that newer LVAD technology which in clinical trials has
been shown to improve clinical outcomes would, in this
real-world effectiveness analysis, demonstrate significant
survival and healthcare expenditure benefits.TagedEn

TagedH1MethodsTagedEn
TagedPStudy Design: We conducted a retrospective cohort study of denovo durable LVADs implanted in the U.S. to assess comparative
effectiveness across different LVAD systems. The goal was to
compare the survival, hospitalization rate, and length-of-stay, and
overall healthcare expenditures in patients implanted with different LVADs; (1) mechanical bearing axial-flow pump (HMII;
Abbott Labs., Chicago, IL); (2) fully magnetically levitated centrifugal flow pump (HM3; Abbott Labs, Chicago, IL); and (3)
other durable LVAD technologies (Other-VADs).TagedEn
TagedPData Sources: The data for baseline characteristics and outcomes were retrieved from the Centers for Medicare and Medicaid
Services (CMS) longitudinal administrative claims files.12,13 The
data for pump technology type, for 2 LVADs; the HM3 and HMII,
were retrieved from the Abbott device registration data. Linking
of the manufacturer device registration data and the Medicare
administrative claims files enabled labeling of the LVAD type for
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each implant common to the manufacturer device registration
database and Medicare claims files.14 Please refer to the Supplemental Appendix for a detailed description of each data source and
linkage methodology.TagedEn
TagedPThe use of Medicare records and linkage to the manufacturer
device registration database was approved through a data use agreement, RSCH-2018-52161, with CMS. The methods for linking data
from the manufacturer device registration database to Medicare
claims files and the research protocol were reviewed by Western
Institutional Review Board (Puyallup, WA) and were granted an
exemption determination, a full waiver of informed consent, and a
Health Insurance Portability & Accountability Act waiver.TagedEn
TagedP articipants: We studied patients with heart failure implanted
P
with a denovo, durable LVAD between January 1, 2014 and
December 31, 2018. The last date of implant was based on the
availability of Medicare data to ensure that each patient had a minimum of 12 months of postimplant follow-up. As of May 2020,
CMS data was available through Dec 31, 2019.TagedEn
TagedP ohort Derivation: A total of 7109 LVAD implants were idenC
tified over the study period, with 5,643 implants representing denovo or primary LVAD implants in the Medicare files that were
not associated with a heart transplant procedure during the LVAD
index hospitalization (Figure 1A & B). Please refer to the Supplemental Appendix for criteria to define de-novo primary VAD
implants (eTable 1).TagedEn
TagedPThe identification of LVADs as HM3 or HMII was done based
on the linkage to the manufacturer device registration database.
Other-VADs were deemed to be implants that were not linked
between the manufacturer device registration database and Medicare claims files. Starting with the de-novo implants, patients were
then excluded based on 5 criteria in the following sequence: (1)
extracorporeal membrane oxygenation (ECMO) during the index
hospitalization; (2) incomplete Part A/B enrollment at index hospitalization; (3) absence of continuous medical coverage 3 months
before the index hospitalization; (4) Health Maintenance Organization (HMO) insurance; and, (5) participation in a pre-market
clinical trial. Patients receiving ECMO were excluded due to possible confounding from the high mortality associated with LVAD
implantation in these patients and the different rates of ECMO use
among the cohort groups. The status of pre-market clinical trial
study participation was determined using the Clinical Trial Number field in the CMS data [https://www.resdac.org/cms-data/varia
bles/clinical-trial-number] and the device registration database
(Figure 1B). The availability of this field was used to exclude all
patients participating in Investigational Device Exemption trials,
whereas post-market study participation of registry participation
was not used as an exclusion for participation in CLEAR-LVAD.
Further, biventricular assist device status was not used as an exclusion criterium because of the low prevalence of biventricular assist
device usage in the time period between VAD implant and discharge. eTable 2 documents the frequency of biventricular assist
device usage across the different type of heart pumps. The final
study cohort consisted of 4,195 patients (821 HM3 pumps, 1,840
HMII pumps and 1,534 Other-VADs) ensuring that none of the
patients represented here were enrolled in MOMENTUM-3 Investigational Device Exemption clinical trial. A sensitivity analysis
to evaluate the influence of exclusion criteria on survival outcomes at 1-year is presented in eTable 3. The only information
provided by the linkage was the device name. All other information was obtained from Medicare claims files on the VRDC.TagedEn
TagedPHealthcare Utilization and Expenditure Analysis: The healthcare burden was assessed in the postimplant period by quantifying
the aggregate number of hospitalizations, number of days spent in
hospital and the payer expenditures associated with these
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hospitalizations. The in-patient hospitalizations and corresponding
expenditures were observed using Part A Medicare claims data
only. Part B Medicare claims data were not used to determine total
healthcare expenditures. The healthcare expenditure analysis was
performed using 2 time-horizons to answer the following questions. (1) “What are the expenditures associated with hospitalizations while patients are ongoing on the original device?” −
aggregate of hospitalizations in the 1-year post discharge - censored at VAD explant, heart transplant or death. This analysis
focused on healthcare encounters for the patient while the individual was on the original device. 2. “What is the expected expenditures of hospitalizations for 1-year post implant depending on
choice of initial VAD?” − aggregate of hospitalizations in the 1year post discharge until and including death. This analysis
focused on healthcare encounters for the patient until death and
includes encounters wherein the original device may be removed
or replaced. Procedure Codes for hospitalizations related to VAD
explant and heart transplant are described in eTable 1.TagedEn
TagedPPayments from hospitals from the dataset were standardized to
2019 U.S. dollars based on the medical (Consumer Price Index)
inflation from the Bureau of Labor Statistics [https://fred.
stlouisfed.org/series/CPIMEDSL]. Standardization to account for
geographic differences was not attempted for 2 reasons. Firstly,
the goal of the economic analysis was to report on the actual
expenditures incurred by Medicare (payer), and secondly, geographic price standardization would effectively be a modeling
exercise that would illustrate the relative cost differential between
geographic regions and not actual expenditures.TagedEn
TagedP tatistical Methods: As the primary end point, we compared the
S
survival at 1-year following pump implantation. Kaplan−Meier survival estimates were calculated, censoring patients at the time of
replacement, explant, or transplantation. The hazard of death for
each pump type (relative to HeartMate-3), after adjusting for patient
factors (which included age, sex, race (White), pre-implant transplant listing status, pre-implant short-term mechanical circulatory
support, preimplant inotrope use, diabetes, hypertension, renal disease, obesity, coagulopathy, cerebral vascular disease, myocardial
infarction, atrial fibrillation, ventricular tachycardia/fibrillation,
peripheral vascular disease, liver disease, pulmonary disease, pulmonary circulation disorder) were compared using a Cox proportionalhazards model (Figure 2A). The comorbidity burden of LVAD
recipients was quantified using the Elixhauser score distribution.15,16TagedEn
TagedPCompeting-risk curves for the total cohort reflect the cumulative
percentages of patients in each group who had an outcome of ongoing device support, heart transplant, device explant/replacement, or
death through 1 year and 2 years (eFigure (1). To analyze survival
in the presence of competing outcomes, the Fine−Grey model was
used to calculate the hazard ratio for death while accounting for the
competing risk of heart transplantation. All tests were 2-tailed, and
pvalues of .05 or less were considered significant.TagedEn
TagedPHealthcare utilization among the implanted cohort was
assessed using the Part A Medicare claims data (in-patient hospitalizations) in the time-period following post-implant until censoring. The events include in-patient hospitalization for any reason,
including LVAD replacement; and follow-up continued until a
patient received a heart transplant, VAD explant, VAD replacement, or death (Figure 3). The all-cause in-patient hospitalizations
events and cumulative length of stay were compared using the
nonparametric bootstrap model.17 The primary end-point comparison is provided at the 1-year timepoint. In this non-parametric
bootstrap analysis, the 2-sided P-values were estimated using the
prepivoting technique for comparisons of event per patient-year
(EPPY) and cumulative length of stay across the pairs of groups:
HM3 vs HMII; HM3 vs Other-VADs. The bootstrap was
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Figure
1
Study population and cohort derivation. (A) Consolidated diagram of the study population. (B) Cohort derivation. (A) ConsoliTagedEn
dated diagram of the study population. The CLEAR-LVAD study cohort included 7109 VAD implants, of which 4,743 were linked (1,368
HeartMate 3 and 3375 HeartMate II) and 2,366 Other-VADs were not linked. Abbreviations: HeartMate II, HMII; HeartMate 3, HM3;
VAD, Ventricular assist device Consolidated diagram of the study population. Medicare VAD implants consists of all heart pump types in
Medicare fee for service enrollees only. The heart pumps in the manufacturer device registration consist of HM3 and HMII implants conducted, amongst all Insurance types (Medicare FFS, Medicare Advantage, Private Insurance, No Insurance). (B) Cohort Derivation Abbreviations: ECMO - extracorporeal membrane oxygenation; HMO, Health maintenance organization; HMII, HeartMate II; HM3, HeartMate
3; VAD, Ventricular assist device. Index Hospitalization is defined as hospitalization for de novo implant.TagedEn
conducted 10,000 times to quantify the variability in the observation and estimate the confidence interval.18TagedEn
TagedPSupporting Analysis using Propensity Matching: We further
conducted a supporting analysis to characterize the outcomes
in a propensity-matched cohort.19,20 Please refer to the

Supplemental Appendix for details of the propensity matching
methodology.TagedEn
TagedPAll analyses were conducted on the CMS Virtual Research
Data Center (VRDC) using SAS Enterprise Guide version 7.15
HF3 (SAS Institute Inc., Cary, NC).TagedEn
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Figure 2
Primary end point of overall 1-year survival. (A) Durable LVAD implants Jan 2014-Dec 2018. (B) Durable LVAD implants Jan
2017-Dec 2018. (A) Durable LVAD implants Jan 2014-Dec 2018 (A) The hazard ratios were adjusted for age, sex, race (White), preimplant
transplant listing status, preimplant short-term mechanical circulatory support, pre-implant inotrope use, diabetes, hypertension, renal disease,
obesity, coagulopathy, cerebral vascular disease, myocardial infarction, atrial fibrillation, ventricular tachycardia and/or fibrillation, peripheral vascular disease, liver disease, pulmonary disease, pulmonary circulation disorder. (B) Durable LVAD implants Jan 2017-Dec 2018.TagedEn

TagedH1ResultsTagedEn
TagedPBaseline Characteristics: The study cohort consisted of 821
HM3, 1,840 HMII and 1534 Other-VADs patients. Demographics and comorbidities for the study cohort are reported
in Table 1. Average age was 63.6 years (57.9% ≥ 65 years)

with a majority being male (78.4%), white (69.6%), and
with a high comorbidity burden (93.9% of patients having
an Elixhauser comorbidity burden > 4; 20.7 § 11.7). The
comorbidity burden was similar across all 3 groups. The
average length of stay for the index VAD hospitalization
was 35.0 § 24.1 days, with a length of stay from VAD
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Figure 3
Total healthcare expenditure conditional on survival over time. (A) Hospitalization expenditures while patients are ongoing on
the original device. (B) Hospitalization expenditures post discharge until death. The plot shows the expected cumulative cost at each time
point, conditional on the subject remaining in the study at that point. p values derived from bootstrap simulation (x10,000). CI - pivotal confidence intervals from non-parametric bootstrap model (x10,000) (A) Hospitalization expenditures while patients are ongoing on the original device. (B) Hospitalization expenditures post discharge until death.TagedEn

implant to discharge of 25.0 § 21.2 days. Clinical management at baseline was characterized by determining the presence of pre-implant short-term mechanical circulatory
support, organ transplant status, and inotrope usage (eTable
4). Preimplant short-term mechanical circulatory support
was used in 25.9% of HM3 patients, 35.1% of HMII
patients, and 37.3% of patients with Other-VADs. Heart
transplant listing before VAD implant was present in 17.4%
of HM3 patients, 10.2% of HMII patients and 24.9% of
Other-VADs. Preimplant inotrope usage, estimated using
the Healthcare Common Procedure Coding System and
National Drug Code codes (eTable 1) from all healthcare
encounters, was present in 28.7% of HM3 patients, 28.8%
of HMII patients, and 24.8% of Other-VADs.TagedEn
P
TagedP rimary Outcomes: Each patient had a minimum followup time of 1 year. There were 117 (14.3%) deaths among
821 HM3 patients, 375 (20.4%) deaths among 1840 HMII
patients, and 375 (24.5%) deaths among 1534 Other-VADs.
The mortality rate at 1-year was significantly lower in

patients with HM3 vs HMII devices (unadjusted hazard
ratio (HR) = 0.57 [95% CI, 0.47-0.70]) and in patients with
HM3 vs Other-VADs (unadjusted HR = 0.53 [95% CI; 0.43
−0.66]). When adjusted for covariates (eTable 5), the 1year HM3 vs HMII HR was 0.64 (95% CI; 0.52−0.79), p<
0.0001; and the 1-year HM3 vs Other-VADs HR was 0.51
(95% CI; 0.42−0.63), p < 0.0001 (Figure 2A). To investigate era effect, a sensitivity analysis was performed limiting
survival analysis to Jan 2017-Dec 2018 (Figure 2B).TagedEn
TagedPThe 2-year mortality rate was significantly lower in
HM3 vs HMII, with an unadjusted HR = 0.57 (95% CI;
0.47−0.70); and in HM3 vs Other-VADs, with an unadjusted HR = 0.53 (95% CI; 0.43−0.66). When adjusted for
covariates, the 2-year HR for HM3 vs Other-VADs was
0.62 (95% CI; 0.52−0.75), p < 0.001, and the 2-year HR
for HM3 vs Other-VADs was 0.51 (95% CI, 0.42−0.61), p
< 0.001. The hazards were proportional, and the survival
outcomes were consistent over the 2-year period (eFigure 2
and eTable 5).TagedEn
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Demographics and Comorbidities at Index Implant

Variable

HeartMate 3 (n = 821) HeartMate II (n = 1,840) Other-VADs (n = 1,534) p valuea

Age, mean (SD), y
Age ≥ 65 years, No. (%)
Female, No. (%)
Race, No. (%)
White
Black
Hispanic
Other\Unknown
Comorbidity history, No. (%)b
Diabetesc
Hypertensionc
Renal diseasec
Obesityc
Coagulopathyc
Cerebral vascular disease,d
Myocardial infarctiond
Atrial fibrillation
Ventricular tachycardia/fibrillation
Peripheral vascular diseasec
Liver diseasec
Pulmonary diseasec
Pulmonary circulation disorderc
Elixhauser score 0-1, No. (%)
Elixhauser score 2-3, No. (%)
Elixhauser score ≥ 4, No. (%)
Elixhauser comorbidity score, mean (SD) [Q1, Q3]

63.6 (11.0)
479 (58.3)
182 (22.2)

64.6 (10.8)
1152 (62.6)
341 (18.5)

62.3 (11.2)
800 (52.2)
383 (25.0)

573 (69.8)
193 (23.5)
16 (1.9)
39 (4.8)

1310 (70.7)
418 (22.7)
35 (1.9)
86 (4.7)

1045 (68.1)
362 (23.6)
42 (2.7)
85 (5.5)

404 (49.2)
703 (85.6)
490 (59.7)
282 (34.3)
85 (10.4)
225 (27.4)
342 (41.7)
418 (50.9)
435 (53.0)
244 (29.7)
108 (13.2)
302 (36.7)
92 (11.2)
37 (4.5)
24 (2.9)
760 (92.6)
18.6 (11.1) [10, 26]

1016 (55.2)
1584 (86.1)
1175 (63.9)
490 (26.6)
285 (15.5)
534 (29.0)
792 (43.0)
983 (53.4)
886 (48.2)
575 (31.3)
294 (16.0)
994 (54.0)
627 (34.1)
47 (2.6)
28 (1.5)
1765 (95.9)
22.4 (12.0) [13, 30]

757 (49.3)
1270 (82.8)
844 (55.0)
396 (25.8)
210 (13.7)
395 (25.7)
593 (38.7)
735 (47.9)
736 (48.0)
413 (26.9)
179 (11.7)
692 (45.1)
380 (24.8)
75 (4.9)
44 (2.9)
1415 (92.2)
19.8 (11.7) [11, 27]

< 0.0001
< 0.0001
< 0.0001
0.48

0.0007
0.0223
<0.0001
<0.0001
0.0018
0.1056
0.0343
0.0062
0.0411
0.0222
0.0012
<0.0001
<0.0001
<0.0001

p-values derived using ANOVA for discrete variables and Chi-square test.
All comorbidities were assessed in the 3 months before index.
c
When definitions were available as both Elixhauser and Charleson, preference was given to the Elixhauser comorbidity definition.
d
Charleson comorbidity code definition used.
a

b

TagedPIn the supporting propensity-score matched analysis of
2,232 patients (744 HM3, 744 HMII, and 744 OtherVADs), the survival rate in the HM3 patients at 1-year was
0.84, and at 2-years was 0.76. Among the matched HMII
patients, the survival at 1-year was 0.76, and at 2-years was
0.64. Among the matched Other-VADs, the survival at 1year was 0.73, and at 2-years was 0.59 (eFigure 3 and
eTable 6). The mortality rate at 1-year was significantly
lower in HM3 vs HMII, with a HR = 0.62 [95% CI; 0.49
−0.79], and in HM3 vs Other-VADs, with a HR = 0.53
[95% CI; 0.42−0.67]. Propensity score density plots show
matching between the cohorts based on the match criteria
(eFigure 4). The patients were well matched with standardized mean difference estimates < 10% for all match parameters (eTable 6). A quartile-based analysis showed the
survival trend was maintained across the four quartiles of
propensity scores (eTable 7).TagedEn
TagedPCompeting-risk curves that reflect the cumulative percentages of patients in each group who had an outcome of
ongoing device support, heart transplant, device explant,
device replacement, or death are shown in eFigure 1. At the
end of 1 year, 78.0% of HM3, 66.5% of HMII and 58.5% of
Other-VADs were ongoing on the original implanted
device. The Fine-Grey model-based HR for death while
accounting for competing risk of heart transplantation at 1
year was 0.64 [95% CI; 0.52−0.79], p < 0.001 for HM3 vs

HMII; and was 0.53 [95% CI; 0.43−0.65], p < 0.001 for
HM3 vs Other-VADs. At the end of 2 years, 70.3% of
HM3, 51.3% of HMII and 43.4% of Other-VADs were
ongoing on the original implanted device (eFigure 1). The
Fine-Grey model-based HR for death while accounting for
competing risk of heart transplantation at 2 years was 0.63
[95% CI; 0.53−0.76], p < 0.001 for HM3 vs HMII; and
was 0.54 [95% CI; 0.45−0.65], p < 0.001 for HM3 vs Other
VADs.TagedEn
H
TagedP ealthcare Encounters: Over 72.6% of patients had hospitalization for any cause in the first year while supported
on the original device, with an event rate of 3.0 events per
patient-year (EPPY). The all-cause hospitalization rates and
cumulative length of stay associated with these in-patient
hospitalizations are reported in Table 2, at the 1-year timepoint. When controlled for time in the study (by patientyears), the HM3 group experienced fewer hospitalizations
per patient-year vs Other-VADs (respectively, 2.8 vs 3.2
EPPY hospitalizations, p = 0.005) and 6.1 fewer hospital
days on average (respectively, 25.2 vs 31.3 days, p <
0.001), as well. As determined from the administrative
claims database, the HM3 patients had the lowest device
explant or replacement rate of 2.6% vs 4.0% for HMII and
3.9% for Other VADs (p < 0.01).TagedEn
H
TagedP ealthcare Expenditure Analysis: The average expenditures related to these hospitalizations are summarized in
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Table 2

The Journal of Heart and Lung Transplantation, Vol 40, No 5, May 2021
Postimplant Healthcare Encounters Within First Year After Implant
HeartMate 3 (n = 812)

Number of hospitalized patients
600 (73.9)
N (%)
All-cause hospitalizationa,
2.8 [2.6 - 3.0]
Events per patient year [95% CI]
Cumulative LOS for All-cause hospitalizations a,
25.2 [23.0 - 27.8]
Days per patient year [95% CI]
Reimbursement for Index Implant Hospitalization,
$ 249,561
$ [95% CI]
[$243,656- $256,383]
Hospitalization cost while patients are ongoing on original device
Average cost at 1-year (CPSY), $ [95% CI]
$ 52,583
[$47,970- $58,025]
Total cost conditional on survival (TCCS) at 1-year,
$ 50,885
$ [95% CI]
[$46,371 - $56,359]
Hospitalization cost in the 1-year post discharge until death
Average cost at 1-year (CPSY), $ [95% CI]
$ 71,846
[$64,438- $81,785]
Total cost conditional on survival (TCCS) at 1-year,
$ 70,566
$ [95% CI]
[$63,465 - $78,964]

HeartMate II (n = 1,840)

Other-VADs (n = 1,534)

1,347 (73.2)

1,093 (71.3)

3.0 [2.9 - 3.2]

3.2 [3.1 - 3.4]

28.5 [26.9 − 30.3]

31.3 [29.0 - 33.9]

$ 266,752
[$261,767- $272,300]

$ 280,0128
[$272,902- $287,395]

$ 63,717
[$60,141 - $67,825]
$ 61,607
[$57,993 - $65,545]

$70,838
[$65,942 - $76,097]
$ 68,832
[$64,215 - $74,100]

$ 84,942
[$79,376 - $90,805]
$ 83,975
[$78,895 - $89,659]

$115,574
[$108,300 - $123,877]
$ 115,382
[$108,617 - $123,968]

Abbreviations: EPPY, events per patient year; LOS, length of stay; CI, pivotal confidence intervals from non-parametric bootstrap model (x100,000);
CPSY, cost per study year; TCCS, total cost conditional on survival
a
Aggregate of hospitalizations in the 1-year post discharge - censored at VAD explant, heart transplant or death.

Table 2. The reimbursement related to the index LVAD
implant for HM3, HMII and Other-VADs was observed to
be $249,561, $266,752 and $280,127 respectively
(Table 2). The difference for HM3 vs HMII was -$17,191,
p < 0.001 and for the HM3 vs Other-VADs was -$30,566,
p < 0.001. The cost per study-year (CPSY) associated with
the hospitalizations at 1-year for the HM3, HMII, and
Other-VADs were $52,583, $63,717 and $70,838/patientyear respectively. The CPSY difference for the HM3 vs
HMII was -$11,134, p < 0.001 (17.5% reduction) and for
the HM3 vs Other-VADs was -$18,255, p < 0.001 (25.8%
reduction).TagedEn
TagedPThe cost implications of these hospitalizations are summarized in Figure 3A. The total cost conditional on survival (TCCS) associated with the hospitalizations at 1-year
for the HM3, the HMII and Other-VADs were $50,885,
$61,607 and $68,832 at 1-year, respectively. The TCCS difference for the HM3 vs HMII was -$10,722, p < 0.001
(17.4% reduction) and for HM3 vs Other-VADs was
-$17,947, p < 0.001 (26.1% reduction). The economic analyses represent actual expenditure differences observed in
the nationally representative Medicare fee for service population that were implanted with each pump type. The viewpoint most relevant to the payer is cost associated with
choice of VAD type. This is summarized in Table 2 section
titled “Hospitalization cost in the 1-year post discharge until
death” which shows the CPSY associated with the hospitalizations at 1-year for the HM3, HMII, and Other VADs:
$71,846, $84,942 and $115,574/patient-year respectively
and TCCS of $70,566, $83,975 and $115,382/patient-year
respectively. The TCCS difference at 11 year for the HM3
vs HMII was -$13,409, p = 0.009 (16.0% reduction) and for
the HM3 vs Other-VADs was -$44,816, p < 0.001 (38.8%
reduction) Figure 3B.TagedEn

TagedPThe healthcare expenditure impact was assessed in the
propensity matched cohort and showed similar trends in
cost difference. In the propensity score matched cohort, the
reimbursement related to the index LVAD implant for
HM3, HMII and Other-VADs was observed to be $
250,685, $ 263,464and $ 276,746 respectively. The difference for HM3 vs HMII was -$12,779, p = 0.020 and for the
HM3 vs Other-VADs was -$26,061, p < 0.001. We
observed that the CPSY associated with hospitalizations at
1-year for the HM3, HMII, and Other-VADs were $53,089,
$62,675 and $73,447 at 1-year respectively (eTable 8) with
a CPSY difference for HM3 vs HMII of -$9,586 p = 0.008
(15.3% reduction) and for HM3 vs Other VADs -$20,358, p
< 0.001 (27.7% reduction).TagedEn

TagedH1DiscussionTagedEn
TagedPThe principal findings of the CLEAR-LVAD study demonstrate that; (1) the HM3 LVAD is associated with improved
survival and decreased rate of postimplant hospitalizations
and days spent in the hospital, when compared to the HMII
LVAD, or with other commercially available VADs; and
(2) healthcare expenditures (Part A claims) assessed from
the perspective of Medicare payments are significantly
lower with the HM3 LVAD, attributed to a reduction in
post-implant hospitalizations.TagedEn
TagedPSurvival of patients with the HM3 LVAD in the
CLEAR-LVAD study was similar to that observed within
the MOMENTUM 3 clinical trial. These data suggest that
real world adoption of this new technology continues to
demonstrate device performance consistent with that
observed in the clinical trial setting and further validates
the within trial observations. We also demonstrated that the
improved outcome on survival and rehospitalization was
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associated with a healthcare expenditure benefit in favor of
the HM3 LVAD, similar to what was reported in an early
within-trial analysis.21TagedEn
TagedPSurvival on 1 of the comparator pumps, the HMII, was
inferior to the HM3 in this real world experience at 2years. This observation was not consistent with that
observed in the MOMENTUM 3 clinical trial, but instead
survival with the HMII was closer to the outcome noted in
the ENDURANCE trial.3,4 The real world experience analyzed in this study was restricted to the Medicare fee for
service-eligible population, a population with a greater
preponderance for lifelong LVAD therapy in and is more
characteristic of the population enrolled in the ENDURANCE trial, whereas the MOMENTUM 3 trial included
patients with either destination therapy or bridge to transplantation intent. Further, patients in the real world experience receiving the HMII could have included patients with
characteristics that would have made them ineligible for
MOMENTUM 3.TagedEn
TagedPIn addition to improved expenditures following discharge for the HM3, the reimbursement for the index
implant admission is more for the Other-VAD than for the
HM3 device. Even though the implants are associated with
the same MS-DRGs, there are various contributing factors
for the observed differences in Medicare expenditures and
include Outlier payments, Geographic location of the Provider (inflation adjusted but not price-standardize Medicare
expenditures), Short-term heart support and Length of stay.
This observation held true in the propensity score matched
cohort as well.TagedEn
TagedPThe methodology used in this study was designed to
identify patients undergoing primary implantation of an
FDA-approved, durable LVAD. Thus, the “Other VADs”
cohort was presumably represented largely by the only
other FDA-approved LVAD in the U.S., the centrifugal
continuous flow pump with hybrid (hydrodynamic and
magnetic) levitation (HVAD; Medtronic, Inc., Minneapolis, MN). Linkage of manufacturer data to Medicare beneficiary records was applied only to the HM3 and HMII arms
of the study cohort. Linkage of the manufacturer database
to the Medicare files served as validation of the methodology to identify patients receiving primary implantation of
an FDA-approved durable VAD. However, this linkage
was not feasible for the Other-VADs arm of the study
cohort because manufacturer data for pumps in that group
were not available. Thus, the number of administrative
coding errors in this arm of the study cohort could potentially be higher than the other 2 study arms and could have
permitted inclusion of some non-FDA-approved durable
VADs in the Other-VADs arm of the study cohort. However, care was taken to ensure n1 of the Other-VADs were
participants of an Investigational Device Exemption clinical trial by reviewing the Clinical Trial Number field in the
CMS data.TagedEn
TagedPAdministrative datasets, such as Medicare, do not capture complete center implant activity and include only
device implants among beneficiaries. Medicare fee for service beneficiaries represent approximately 45% of durable
LVAD implants in the U.S.22 Thus, the real world
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experience in this study excludes patients receiving the
HM3 who were not Medicare eligible. Whether the real
world experience in non-Medicare beneficiaries is similar
to Medicare beneficiaries or similar to the clinical trial
experience remains unknown. Recent data from The Society of Thoracic Surgeons Interagency Registry of Mechanically Assisted Circulatory Support (Intermacs) have
demonstrated similar survival for the HM3 in a real world
setting in a population including Medicare and non-Medicare patients.10 In a recent trial analysis of MOMENTUM
3, Goldstein et al. compared patients by initial therapeutic
intent and demonstrated that the survival and adverse
events, such as stroke rates, were not materially different in
the bridge-to- transplant population compared with the
older destination-therapy cohort.2TagedEn
TagedPThere are several limitations to this study. This was a
real world analysis of patients receiving durable VAD therapy and was a retrospective, observational study design
involving nonrandomized treatment assignments. Thus,
confounders not accounted for in the study analyses may
contribute to differences in the outcomes of the 3 study
arms. Rigorous comparison of comorbid conditions and status of transplant eligibility, inotrope use, and temporary
mechanical circulatory support use were carefully assessed
among study arms to minimize cofounders. Important, clinically relevant differences between the HM3 and the OtherVADs group were noted for pulmonary disease, pulmonary
circulation disorders, and frequency of pre-implant shortterm mechanical circulatory support between admission
and durable device implant, which were more frequent for
the Other-VADs cohort. However, the Other-VADs cohort
was characterized by much greater representation of
bridge-to-transplant candidates, of whom generally indicate
a population with fewer comorbid conditions. The proportion of patients receiving a heart transplant at 2-years was
twice that with the Other-VADs compared to the HM3.
Administrative coding, however, may not be as precise as
granular clinical data available from a clinical device registry in assessing risk of co-morbid conditions. Multiple statistical methodologies including propensity matching, were
therefore used to minimize differences, where feasible,
between groups. Additionally, more HM3 devices were
placed in the later years of the study compared to HMII
devices and Other-VADs. Thus, improvements in patient
management strategies over time could have created confounding with respect to the cost associated with management of adverse events. We also do not report the adverse
event profiles, nor do we evaluate the principal reasons for
the observed survival benefit, or the causes of hospitalizations. We intentionally did not attempt to analyze this information since we deemed that level of evaluation to not
provide sufficient robustness or granularity due to the introduction of coding errors, misclassification, and the fact that
multiple adverse events tend to define most hospitalizations
and it is difficult to adjudicate the principal drivers from
such a database. We therefore maintained the evaluation to
those areas of robustness including death rates, overall hospitalizations and days in the hospital and overall costs
incurred.TagedEn
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TagedH1ConclusionTagedEn
TagedPIn this analysis of a large U.S. administrative dataset that
details real world VAD therapy, we observed that the HM3
LVAD demonstrated better survival to that of other contemporary LVAD systems. Furthermore, we demonstrated that
the HM3 is associated with fewer hospitalizations and hospital days incurred after implantation, and a reduction in
overall expenditure, when compared to other commercially
available LVADs. These data validate the efficacy of the
HM3 in a real world experience and support previous clinical trial observations.TagedEn

TagedH1PerspectivesTagedEn
TagedPCompetency in Medical Knowledge: In a real world setting of Medicare beneficiaries undergoing implantation of a
durable LVAD, a totally magnetically levitated centrifugal
continuous flow device (HeartMate 3), is associated with
improved survival and lower hospital resource utilization
and Medicare expenditures.TagedEn
TagedPTranslational Outlook: Further research is needed to
understand the major benefits that contribute to reduction in
hospital resource utilization, Medicare expenditures and
survival for the HeartMate 3 left ventricular assist device.TagedEn
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